
The Life Sciences Industrial Strategy was supposed to forge a path forward for the industry, despite pressures from Brexit, to …

A Cancer Research UK-funded study undertaken by the University of Glasgow has revealed that representation and coverage of cancer patients …

“Jon’s appointment comes at an exciting time for the company” reads the company press on annoucing its new Managing Director …

A large study looking at the public’s use of anticholinergic drugs, such as those used to treat depression and Parkinson’s, …

Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase …

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and …

With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes …

From March onwards, Takeda has been nudging a deal with Shire onwards through repeatedly improved offers, which has seen the …

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced that sodium valproate, a drug used in the treatment …

FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …

AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it …

Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …

Shares in Prothena have dropped by close to 70% on the news that two of its trials into its lead …

Tony Green discusses the difficulty in pinning down his diagnosis of the irregular heart rhythm condition, until his use of …

Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

AB Science has revealed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …

Fresenius has announced its intention to terminate the merger agreement with Akorn, over the $4.75 billion deal that the two …

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …